Dermapharm completed the acquisition of Allergopharma from Merck.

Dermapharm, a manufacturer of off-patent branded medicines, completed the acquisition of Allergopharma, an internationally operating pharmaceutical company specialized in in-vivo diagnosis and treatment, from Merck, a science and technology company. Financial terms were not disclosed. The transaction encompasses the Allergopharma business in Europe and Asia, including the therapeutic and diagnostic product portfolio as well as the production site in Reinbek near Hamburg. Allergopharma’s adrenaline autoinjector development project for the treatment of anaphylactic reactions is not part of the transaction and will remain with Merck KGaA, Darmstadt, Germany.